Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue

Prostate‐specific antigen (PSA/KLK3) and human kallikrein 2 (hK2/KLK2) belong to the human kallikrein gene family. These two highly homologous genes are specifically expressed in the prostate under androgen control. Expression of these is regulated by similar mechanisms but changes in their relative expression have been observed in prostate cancer.

[1]  P. Riegman,et al.  Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species , 1991, Molecular and Cellular Endocrinology.

[2]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[3]  N. Heuzé-Vourc’h,et al.  Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen). , 2003, European journal of biochemistry.

[4]  R. Kontermann,et al.  Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen , 1999, British Journal of Cancer.

[5]  M. Serio,et al.  Real-Time RT-PCR for the Measurement of Prostate-Specific Antigen mRNA Expression in Benign Hyperplasia and Adenocarcinoma of Prostate , 2003, Clinical chemistry and laboratory medicine.

[6]  D. Tindall,et al.  Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.

[7]  George M Yousef,et al.  Human tissue kallikreins: a family of new cancer biomarkers. , 2002, Clinical chemistry.

[8]  P. Riegman,et al.  Molecular cloning and characterization of novel prostate antigen cDNA's. , 1988, Biochemical and biophysical research communications.

[9]  A. Bjartell,et al.  Expression and characterization of trypsinogen produced in the human male genital tract. , 2000, The American journal of pathology.

[10]  T. Isono,et al.  A novel form of prostate-specific antigen transcript produced by alternative splicing. , 2000, Cancer research.

[11]  M. Wirth,et al.  Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. , 2003, International journal of oncology.

[12]  C. Young,et al.  The expression of a variant prostate-specific antigen in human prostate. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[14]  T. Piironen,et al.  Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. , 2000, Urology.

[15]  D. Tindall,et al.  Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. , 1999, Urology.

[16]  W. Rychlik,et al.  Priming efficiency in PCR. , 1995, BioTechniques.

[17]  D. Tindall,et al.  In situ hybridization of prostate-specific antigen mRNA in human prostate. , 1990, The Journal of urology.

[18]  C. Croce,et al.  Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. , 1994, Cancer research.

[19]  G G Klee,et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.

[20]  B. Morris,et al.  Primary structure of a human glandular kallikrein gene. , 1987, DNA.

[21]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[22]  U. Bergmann,et al.  Activation of Type IV Procollagenases by Human Tumor-associated Trypsin-2* , 1997, The Journal of Biological Chemistry.

[23]  J. Holaday,et al.  Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo , 2003, The Prostate.

[24]  D. Tindall,et al.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. , 1991, Cancer research.

[25]  D. Mullins,et al.  The role of proteinase in cellular invasiveness , 1983 .

[26]  B. Tribukait,et al.  Tissue PSA from fine‐needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy , 1999, The Prostate.

[27]  H. Lilja,et al.  Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. , 1997, Biochemical and biophysical research communications.

[28]  T. Piironen,et al.  In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. , 1998, Urology.

[29]  Hongyu Wu,et al.  Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[31]  G. Kristiansen,et al.  Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. , 2000, Urology.

[32]  R. Barth,et al.  Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes. , 1998, International journal of molecular medicine.

[33]  A. Palotie,et al.  Accurate determination of relative messenger RNA levels by RT-PCR , 1999, Nature Biotechnology.

[34]  H. Lilja,et al.  Molecular cloning of human prostate specific antigen cDNA , 1987, FEBS letters.

[35]  L. Mintz,et al.  Unusual Alternative Splicing within the Human Kallikrein Genes KLK2 and KLK3 Gives Rise to Novel Prostate-specific Proteins* , 2002, The Journal of Biological Chemistry.

[36]  A. Palotie,et al.  Relative levels of SCCA2 and SCCA1 mRNA in primary tumors predicts recurrent disease in squamous cell cancer of the head and neck , 2001, International journal of cancer.

[37]  N. Heuzé-Vourc’h,et al.  Characterization of PSA-RP2, a protein related to prostate-specific antigen and encoded by alternative hKLK3 transcripts. , 2001, European journal of biochemistry.

[38]  O. Itkonen,et al.  Biology and function of tumor-associated trypsin inhibitor, TATI. , 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[39]  J. Trachtenberg,et al.  Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Sokoll,et al.  Prostate‐specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo , 2003, The Prostate.

[41]  U. Stenman,et al.  Prostate-specific antigen and other prostate cancer markers. , 2000, Urology.

[42]  K. Porvari,et al.  Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue , 2001, Cancer.

[43]  N Heuzé,et al.  Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. , 1999, Cancer research.